News Sentiment

TAK sentiment intelligence

Takeda Pharmaceutical Co Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 58 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 16.56 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

90/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.3% over one week, +4.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 90/100 classification
One-week reaction -1.3% Price digesting
Trend fit Trend inactive 4.1% over four weeks
Fair value 16.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 33
Quartr 5
Market source 4
Simply Wall Street 3
www.marketscreener.com 1
Jakarta Globe 1
Investing.com Nigeria 1
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 50
Earnings 4
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
www.marketscreener.com Direct company coverage

Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

Takeda Pharmaceutical announced it will host an earnings call on July 30, 2026, to present its first-quarter results for fiscal year 2026. Key participants will include President and CEO Julie Kim, CFO Milano Furuta, and President of R&D Andy Plump. The event will be held on Zoom

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 23:41
Source
www.marketscreener.com
Quartr Direct company coverage

Takeda Pharmaceutical Company (4502) 44th Annual J.P. Morgan Healthcare Conference summary

Takeda Pharmaceutical Company presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic transformation towards an innovation-driven pharmaceutical business with a focus on gastroenterology, neuroscience, and oncology. The company highlighted eight la

Tone
Positive 80/100
Event
Market update
Published
14 Jul 2026 22:13
Source
Quartr
Jakarta Globe Direct company coverage

Takeda to Invest $30 Million in Indonesia's Plasma Medicine Industry

Japanese biopharmaceutical company Takeda plans to invest $30 million in the initial phase of developing Indonesia's plasma-derived medicines ecosystem. This investment, spread over two years, aims to establish a nationwide plasma collection network and will support technology tr

Tone
Positive 75/100
Event
Market update
Published
14 Jul 2026 10:50
Source
Jakarta Globe
Investing.com Nigeria Direct company coverage

Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com

This article briefly reports on a Form 144 filing by Takeda Pharmaceutical Company Limited for July 13th. The filing indicates insider intent to sell restricted stock. This is a standard regulatory disclosure within financial markets.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 23:44
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Takeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSE

Takeda Pharmaceutical Company Limited has filed a Form 144 notice to sell up to 7,889 American Depositary Shares (ADSs) on the NYSE through Interactive Brokers LLC, on or after July 13, 2026. The aggregate market value of these ADSs is indicated as $132,148.97. The filing also no

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
Stock Titan
Stock Titan Direct company coverage

[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filing

Takeda Pharmaceutical Company Limited filed a Form 144 SEC notice regarding the proposed sale of 190,406 American Depositary Shares (ADSs) on the NYSE. These ADSs were acquired through vested Restricted Stock Unit Awards as part of compensation on July 1, 2026. Interactive Broker

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
Stock Titan
Stock Titan Direct company coverage

Takeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850

Takeda Pharmaceutical Company Limited has filed a Form 144 notice for the proposed sale of 24,887 American Depositary Shares (ADSs) through Interactive Brokers LLC. The aggregate market value of these shares is approximately $416,850 and the sale is expected to occur on or about

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
Stock Titan
Pharmaceutical Technology Direct company coverage

Takeda and Indonesia partner on plasma-derived therapies

Takeda is collaborating with the Indonesian Government to establish a plasma ecosystem and improve access to plasma-derived medicinal products (PDMPs) in Indonesia. The company plans to invest up to $30 million to launch a national plasma donation pilot program, with initial dona

Tone
Positive 81/100
Event
Market update
Published
13 Jul 2026 09:45
Source
Pharmaceutical Technology
Quartr Direct company coverage

Takeda Pharmaceutical Company (4502) TD Cowen 46th Annual Health Care Conference summary

Takeda Pharmaceutical Company presented at the TD Cowen 46th Annual Health Care Conference, highlighting a strategic overview that included successful Phase III results for three new molecular entities (rusfertide, oveporexton, and zasocitinib) in 2025 and an upcoming CEO transit

Tone
Positive 73/100
Event
Earnings
Published
11 Jul 2026 23:10
Source
Quartr
Quartr Direct company coverage

Takeda Pharmaceutical Company (4502) Study Update Summary

Takeda Pharmaceutical Company (4502) released a study update for Oveporexton, an oral orexin receptor 2 agonist, which showed significant and clinically meaningful improvements in treating narcolepsy type 1 (NT1) across multiple endpoints. Two global Phase III trials demonstrated

Tone
Positive 74/100
Event
Market update
Published
11 Jul 2026 10:39
Source
Quartr
Simply Wall Street Direct company coverage

Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?

Takeda Pharmaceutical (TSE:4502) has partnered with Insilico Medicine's Pharma.AI platform for drug discovery, leading to renewed investor interest. Despite an 8.5% year-to-date share price increase and a 26.82% one-year return, a recent 90-day decline of 6.94% prompts questions

Tone
Positive 66/100
Event
Market update
Published
10 Jul 2026 16:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Takeda (NYSE: TAK) outlines board independence, ESG and shareholder engagement

Takeda Pharmaceutical Company Limited has filed a detailed Corporate Governance Report, highlighting its compliance with Japan’s Corporate Governance Code. The report emphasizes the company's commitment to board independence with a majority of independent external directors, robu

Tone
Positive 61/100
Event
Market update
Published
09 Jul 2026 09:48
Source
Stock Titan
Quartr Direct company coverage

Takeda Pharmaceutical Company (4502) Q4 2025 earnings summary

Takeda Pharmaceutical Company announced its Q4 2025 earnings, reporting significant revenue and core operating profit growth, driven by strong performance in growth and launch products. The company also highlighted efficiency program successes, pipeline advancements, and an incre

Tone
Positive 70/100
Event
Earnings
Published
08 Jul 2026 22:11
Source
Quartr
Moomoo Direct company coverage

Takeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Plan

Takeda Pharmaceutical announced it has completed the issuance and disposal of shares as part of its incentive plan. The shares were allocated to a trust for the "Board Benefit Trust (BBT)" and "Employee Stock Ownership Plan (ESOP)" schemes. This move aims to enhance shareholder v

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:42
Source
Moomoo
Quartr Direct company coverage

Takeda Pharmaceutical Company (4502) Q1 2026 earnings summary

Takeda Pharmaceutical Company's Q1 FY2025 revenue declined 8.4% year-over-year to JPY 1,106.7 billion due to Vyvanse's generic erosion and FX headwinds, but net profit rose 30.4% to JPY 124.2 billion. Growth and launch products, comprising 50% of revenue, grew 5% at CER, showing

Tone
Positive 66/100
Event
Earnings
Published
08 Jul 2026 09:42
Source
Quartr
Stock Titan Direct company coverage

Takeda (TAK) completes long-term incentive share issuance and treasury share disposal

Takeda Pharmaceutical Company Limited announced the completion of its long-term incentive share issuance and treasury share disposal for employees outside Japan. The company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, totaling 85,229,400,450 yen. Thi

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 09:40
Source
Stock Titan